綠竹生物-B(02480.HK)上半年淨虧損達1.1億元 研發開支同比增長142.4%
格隆匯8月21日丨綠竹生物-B(02480.HK)公佈中期業績,截至2024年6月30日止六個月,集團其他收入為人民幣973.2萬元,同比增長82.3%;期內虧損為人民幣1.10億元,虧損同比增長38.5%。研發開支為人民幣8037.6萬元,同比增長142.4%。
於2024年上半年,公司已實現多項公司重大里程碑。於2023年9月在中國啟動公司核心產品LZ901的多中心、隨機、雙盲、安慰劑對照III期臨牀試驗後,公司於2024年1月已完成共26,000名40歲及以上健康受試者的入組。於2024年4月,集團於美國及澳洲就其核心產品獲授發明專利。在此基礎上,集團於2024年6月就LZ901舉行中期總結會議,討論其在中國的III期臨牀試驗。此外,於2024年4月,公司亦已於廣東省珠海市完成二期生產設施的建設,該生產設施的規劃建築面積約為12萬平方米,其中7.2萬平方米為生產廠房。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.